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Background: Schistosomiasis is a neglected tropical disease with high morbidity and mortality in the world.
Currently, the treatment of this disease depends almost exclusively on praziquantel (PZQ); however, the emergence
of drug resistance to PZQ in schistosomes makes the development of novel drugs an urgent task. Aldose reductase
(AR), an important component that may be involved in the schistosome antioxidant defense system, is predicted as
a potential drug target.
Methods: The tertiary structure of Schistosoma japonicum AR (SjAR) was obtained through X-ray diffraction method
and then its potential inhibitors were identified from the Maybridge HitFinder library by virtual screening based on
this structural model. The effects of these identified compounds on cultured adult worms were evaluated by
observing mobility, morphological changes and mortality. To verify that SjAR was indeed the target of these
identified compounds, their effects on recombinant SjAR (rSjAR) enzymatic activity were assessed. The cytotoxicity
analysis was performed with three types of human cell lines using a Cell Counting Kit-8.
Results: We firstly resolved the SjAR structure and identified 10 potential inhibitors based on this structural model.
Further in vitro experiments showed that one of the compounds, renamed as AR9, exhibited significant inhibition in
the activity of cultured worms as well as inhibition of enzymatic activity of rSjAR protein. Cytotoxicity analysis
revealed that AR9 had relatively low toxicity towards host cells.
Conclusions: The work presented here bridges the gap between virtual screening and experimental validation,
providing an effective and economical strategy for the development of new anti-parasitic drugs. Additionally, this
study also found that AR9 may become a new potential lead compound for developing novel antischistosomal
drugs against parasite AR.
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Schistosomiasis is a major tropical disease in developing
countries. It is estimated that over 200 million people
from 76 countries and territories are suffering from this
disease [1]. The disease is usually caused by one of three
schistosome species: Schistosoma japonicum, Schistosoma
mansoni and Schistosoma haematobium. In China, S.
japonicum is the primary pathogen of this disease [2]. Cur-
rently, the treatment of schistosomiasis depends almost
exclusively on praziquantel (PZQ), and this drug has been
widely used for nearly 40 years because of its high efficacy
but low cost [3]. However, the long-term utilization of one
drug can result in drug-resistant parasites. Decreased sus-
ceptibility of S. mansoni and S. haematobium to PZQ has
already been identified in previous studies [4,5]. Although
no reduced susceptibility of S. japonicum has been proven
to date, the efficacy of this drug is found to vary in differ-
ent strains within this species [6]. Therefore there is an
urgent need to develop novel antischistosomal lead com-
pounds, and the identification of ideal drug targets is an
important step toward this goal.
Antioxidant defense is an essential mechanism for schis-
tosomes to cope with damage from host immune- and
self-generated reactive oxygen species (ROS) [7]. Many
redox-associated proteins such as thioredoxin glutathione
reductase (TGR), peroxiredoxin (Prx) and thioredoxin
(Trx) have been demonstrated to be involved in this sys-
tem in previous studies [8-11]. Most of these proteins are
considered as potential drug targets, as one example, two
recently discovered prospective antischistosomal com-
pounds, auranofin and oxadiazoles, were developed with
TGR as drug target [9,12]. Although no research has
shown that S. japonicum AR participates in the antioxi-
dant pathway, in other organisms, AR is believed to be an
important antioxidant component. Spycher et al. [13]
found that the levels of AR mRNA were up-regulated
under oxidative stress in rat smooth muscle cells. Further-
more, the levels of AR expression as well as its activity
were increased during hyperglycemia and other oxidative
stress-induced diseases in humans [14,15]. Additionally,
many byproducts of oxidative stress, such as methyl-
glyoxal and 3-deoxyglucosone, have been shown to be
excellent substrates of AR [16]. Considering both these
conclusions and the antioxidant requirement of schisto-
somes, it is reasonable to speculate that SjAR might also
participate in the antioxidant pathway and protect the
worms from host ROS attack. In addition to the above,
AR has also been demonstrated to play an important role
in aldehyde detoxification, steroid metabolism, energy
supply, cellular proliferation, apoptosis and senescence
[17-20]. Its multiple functions suggest that it may repre-
sent a key enzyme in schistosomes.
In the present study, we successfully resolved the ter-
tiary structure of recombinant SjAR and identified 10inhibitor candidates through molecular docking based
on the obtained structural model. We then assessed the
activity inhibition of these compounds on cultured
worms. To further confirm that the SjAR protein was in-
deed the target of the selected compounds, we investi-
gated the effect of the identified compounds on the
enzymatic activity of recombinant SjAR (rSjAR). The
cytotoxicity of the active compounds towards the host
cell was evaluated as well. Finally, one compound,
renamed as AR9, was determined to effectively inhibit
the activity of cultured worms but show relatively low
cytotoxicity against host cells, which suggests its poten-
tial use as a lead compound from the selected candidate
inhibitors. The work presented here bridges the gap be-
tween virtual screening and experimental validation,
providing an effective and economical strategy to de-
velop novel anti-parasitic drugs.
Methods
Materials
Protein crystallization kits were purchased from Hampton
Research Corporation (USA). NADPH was obtained from
Roche (Switzerland). DL-glyceraldehyde and PZQ came
from Sigma (USA). Small molecules identified by virtual
screening were purchased from Maybridge HitFinder li-
brary (USA). RPMI 1640, DMEM and bovine serum
(Newborn calf serum and fetal bovine serum) came from
Invitrogen (USA). The recombinant SjAR-pET28a plasmid
was constructed previously and stored in our laboratory.
BL21 (DE3) and Hep G2 cells were also stored in our la-
boratory. 293T and HeLa cell lines were kindly provided
by Hongyan Wang (School of Life Sciences, Fudan Uni-
versity, China). S. japonicum cercaria was provided by the
pathogen biology laboratory of the National Institute of
Parasitic Diseases, Chinese Center for Diseases Control
and Prevention. Specific pathogen-free Kunming female
mice were purchased from the Shanghai Experimental
Animal Center, Chinese Academy of Sciences (China).
Expression and purification of rSjAR
The recombinant plasmid SjAR-pET28a was transfor-
med into E. coli BL21 (DE3) cells and cultured in Luria-
Bertani (LB) medium plus 50 μg/ml kanamycin.
Isopropylthio-β-D-galactoside (IPTG), 1 mM, was added
to the medium to induce protein expression, and then
the cells were cultured for an additional 6 h. The cells
were harvested by centrifugation, and pellets were
resuspended in lysis buffer (20 mM Tris–HCl, 500 mM
NaCl, 1 mM PMSF, pH 8.0). Subsequently, the cells were
disrupted by ultrasonic waves for 5 min in 2 s pulses at
160 W. The whole cell lysate was clarified by centrifuga-
tion at 10,000 × g for 30 min at 4°C. The resulting super-
natant was purified sequentially using immobilized
metal ion affinity chromatography, anion-exchange
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raphy. The purified protein was stored in 20 mM Tris–
HCl (pH 6.2), 100 mM NaCl, 5 mM DTT. The rSjAR
protein was concentrated by ultrafiltration using
Millipore Ultrafiltration System with a molecular weight
cut off at 10 KDa. Protein concentration was determined
by a Bradford Protein Assay Kit (Glory, USA).
Crystallization
Initial crystallization conditions were screened in Tissue
Culture Test Plates 24 (TPP) by the hanging-drop
method at 291 K, using the sparse-matrix method [21]
implemented in the Crystallization Screens Kits (in-
cluded Index, Crystal Screen, Crystal Screen 2, PEG/Ion
Screen and PEG/Ion 2 Screen and SaltRx) from Hampton
Research. Three protein concentrations were adopted:
24 mg/ml, 12 mg/ml and 6 mg/ml. A total of 1 μl protein
solution was mixed with 1 μl well solution and equili-
brated against 200 μl reservoir solution. Crystallization
leads were identified in over 10 of these conditions. One
initial condition (PEG/Ion Screen: 0.2 M Sodium fluoride,
20% w/v Polyethylene glycol 3,350, pH 7.3), which pro-
duced single crystals, was optimized to obtain crystals
suitable for diffraction analysis. The final optimal condi-
tions were 12 mg/ml protein and a reservoir solution
consisting of 0.2 M Sodium fluoride, 30% w/v, Polyethyl-
ene glycol 3,350 (pH 7.1).
Data collection and processing
Crystals were flash-cooled in liquid nitrogen with a cryo-
protectant containing only reservoir solution. Diffraction
data were collected at Beamline BL17U at the Shanghai
Synchrotron Radiation Facility and processed with the
package HKL-2000 using routine procedures [22]. The ini-
tial phases were calculated in the program PHASER [23],
from the CCP4 suites, using a structure known H. sapiens
AR (HsaAR, PDB ID: 1ZUA) as a search model. The final
model was manually built with COOT [24]. All computa-
tional refinements were performed using the refinement
module phenix.refine of the PHENIX package [25]. The
model quality was checked with the PROCHECK pro-
gram, which showed good stereochemistry according to
the Ramachandran plot for the structure.
Molecular docking
To identify potential inhibitors of SjAR, the Maybridge
HitFinder library, which contains approximately 80,000
compounds, was chosen for in-silico screening with the
model of the rSjAR protein. Molecular docking was firstly
performed with Sybyl v8.0 Surflex-Dock (www.tripos.com)
followed by docking the top 5% hits with AutoDock 4.2
(http://autodock.scripps.edu/). The top 100 scoring com-
pounds were selected out and exported to an Excel spread-
sheet. To increase the selectivity of these compounds, theywere also docked into the HsaAR protein. The final
obtained compounds conformed to the following princi-
ples: 1) the SjAR protein-compound binding free energy
was lower than −9 kCal/mol; and 2) the compound
showed a greater binding preference to the SjAR protein
than to HsaAR (the difference of binding free energy was
higher than 2 kCal/mol).
Inhibition studies on cultured worms
Mice infected with 80–100 cercariae were killed at
35 days-post-infection for worm collection. S. japonicum
adult worms were obtained by perfusion and washed three
times with sterile saline. Next, the worms were transferred
to RPMI 1640 medium containing 300 μg/ml penicillin,
300 μg/ml streptomycin, 0.25 μg/ml amphotericin and
20% fetal bovine serum and then cultured for 2 h to make
the worms discharge their gut contents. Two pairs of
worms with good activity were selected and transferred to
each well of a 24-well plate containing 2 ml of the preced-
ing culture medium. Stocking solutions of compounds
were prepared by dissolving 2 mg of the compounds in
0.4 ml dimethyl sulfoxide (DMSO) and then were added
to a series of final concentrations (for initial screening,
three concentrations of 5 μg/ml, 25 μg/ml and 50 μg/ml
were assessed, while for the second screening, five concen-
trations of 1.25 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml, and
20 μg/ml were assessed). The worms in the control group
were treated with equal amounts of the compound carrier.
A PZQ treated group was also observed as a positive con-
trol. The test was repeated three times, and for each ex-
perimental condition, 12 worms in 3 wells were tested.
The worms were cultured at 37°C in an incubator with
5% CO2. The worm mobility, morphological changes and
mortality were observed under an inverted microscope at
2 h, 24 h, 48 h and 72 h. Parasite death was defined as
non-detectable activity in 2-minutes, accompanied by
morphological and tegumental alterations [26]. The me-
dian lethal concentration (LC50) values for the identified
active compounds were calculated by the software SPSS
18.0, with a confidence interval of 95%.
Effect of compound AR9 on rSjAR enzymatic activity
The enzymatic assay was described previously [27]. Briefly,
the reaction was performed in 120 mM PBS buffer (pH
6.2), containing 1.5 mM DL-glyceraldehyde, 0.15 mM
NADPH and 0.15 μM rSjAR in a final volume of 200 μl.
The mixture was first incubated at 37°C for 5 min, and
then the reaction was initiated by adding the substrate of
NADPH. For inhibition analysis, AR9 was added to the
same reaction system to final concentrations of 5 μg/ml,
10 μg/ml, 20 μg/ml and 40 μg/ml. The reaction process
was determined by monitoring the absorbance reduction
at 340 nm due to the depletion of NADPH using a Model
680 Microplate Reader (Bio-Rad, USA).
Table 1 X-ray data-collection and structure refinement
statistics
Data collection and processing
Processing software HKL2000
Synchrotron, beamline SSRF, BL17U
Wavelength (Å) 0.9791
Space group P21212
Unit cell parameters a, b, c (Å, °) a = 67.49, b = 91.00, c = 54.67
Resolution range (Å)1 30.0-2.20 (2.28-2.20)
Unique reflections 17617
Redundancy 6.4 (6.5)
Completeness (%) 99.8 (99.9)






Average B factor, (Å2) 17.9
RMSD from ideal geometry, bonds (Å) 0.007
RMSD from ideal geometry, angles (°) 1.023
Protein atoms 2452
Water molecules 225
Residues in the Ramachandran plot
Most favored region (%) 92.5
Allowed region (%) 7.5
Generously allowed region (%) 0
Disallowed region (%) 0
1Values in parentheses are for the highest resolution shell.
2Rfree = ∑Test||Fobs| –|Fcalc||/∑Test |Fobs|, where “Test” is a test set of about 5% of
the total reflections randomly chosen and set aside before refinement.
Figure 1 Structure and predicted cofactor binding area of the SjAR p
colored yellow and loops colored green. B. The structure of SjAR is shown
in cofactor binding (by homology with H. sapiens AR) colored yellow.
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Schistosome samples were fixed with 2.5% glutaraldehyde
in PBS buffer for 2 h and were then washed thoroughly
three times with PBS buffer. The samples were fixed again
in 1% osmium tetroxide in PBS buffer. After ethanol dehy-
dration and critical point drying, they were mounted on
microscope stubs, followed by gold sputtering for 3 min in
an IB-3 ion-sputtering instrument. The SEM scanning was
performed on an S-520 SEM (Hitachi, Japan) instrument
with an accelerating voltage of 20 kV [28].
Cytotoxicity assay
Cytotoxicity analysis was performed with three types of
human cell lines (Hep G2, 293T and Hela cell lines) using
a Cell Counting Kit-8 according to the protocol provided
by the manufacturers (Beyotime, China). Briefly, the cells
were cultured in a 96-well plate containing 100 μl DMEM
medium (containing 10% fetal bovine serum) at a density
of 5,000 cells per well at 37°C in 5% CO2. The cells were
allowed to recover for 24 h and then exposed to various
concentrations of compound or compound-carrier. When
the cells in the negative control group (carrier alone) cov-
ered more than 90% of the surface of the well, 10 μl of
WST-8 chromogenic agent was added to each well and
then continuously incubated for 30 min. The absorbance
at 450 nm was determined by using a Model 680
Microplate Reader (Bio-Rad, USA).
Ethical approval
The animal work was approved by the Ethics Committee
of the National Institute of Parasitic Diseases, Chinese
Center for Disease Control and Prevention in Shanghai,
China (Ref No: 20100525–1). Animal care and all proce-
dures involving animals were performed in strict accord-
ance with the Guidelines for the Care and Use of
Laboratory Animals of the Ministry of Science and Tech-
nology of People’s Republic of China ([2006]398). All ef-
forts were made to minimize suffering.rotein. A. Cartoon diagram of SjAR with α-helices colored red, β-sheets
in a surface representation with the regions predicted to be involved
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Structure determination and description
The rSjAR protein crystals diffracted to a resolution of
2.2 Å and belonged to the space group P21212 with the
unit cell parameters a = 67.49, b = 91.00 and c = 54.67 Å.Table 2 The finally obtained 10 candidate compounds










































































−9.15 −3.78 5.37Residues 211–221 were disordered and were not built
into the structure model. After structure solution and
computational refinement, the final model of SjAR, vali-
dated using PROCHECK, had 92.5% of residues in the
most favored regions of the Ramachandran plot and
7.5% of residues in the additionally allowed regions. The
structure had Root Mean Square Deviation (RMSD)
from ideality for bond lengths of 0.007 Å and for an
angle of 1.023°. Further data collection and computa-
tional refinement statistics are summarized in Table 1.
The overall structure of SjAR (PDB ID: 4HBK) showed
an (α/β)8 barrel topology, which is the typical characteris-
tic of the aldo-keto reductase superfamily (Figure 1A)
[29,30]. By comparing the amino acid sequence with the
homologous HsaAR protein, we found both the residues
at the substrate-binding site (Asp43, Tyr48, Lys77 and
His110) and at the predicted inhibitor-binding sites (Tyr48,
His110 and Trp111) were conserved [30,31]. These residues
were located in the interior of the β-barrel, which provided
a target area to begin docking (Figure 1B).
Structure-based virtual screening
Although the SjAR protein shares only 51% sequence
identity with HsaAR (PDB ID: 1ZUA), their tertiary
structures are highly similar (RMSD: 0.865 Å). The AR
protein family has highly conserved substrate binding
sites, and all the nearby residues surrounding the bind-
ing sites are the same, which suggests that the region
would be somewhat unsuitable for docking. Therefore,
we compared the structural divergence near the poten-
tial inhibitor binding regions. Compared with the known
HsaAR-tolrestat complex structure [30], in the SjAR
structure, Lys257 penetrated into the binding regions,
while Gln297 and Trp20 were moved away. Additionally,
Phe293 replaced Cys299 to participate in the formation of
the hydrophobic pocket. However, all of these residuesFigure 2 Time-dependent survival rate of worms treated with
different concentrations of compound AR9. The concentrations
of AR9 used were 1.25 μg/ml (asterisk), 2.5 μg/ml (circle), 5 μg/ml
(triangle), 10 μg/ml (square) and 20 μg/ml (diamond).
Figure 3 Observation of worms exposed to compound AR9 under optical microscopy. A. Worms treated with 5 μg/ml of AR9 for 48 h; B.
treatment with 10 μg/ml of AR9 for 72 h; C. Positive control group, treatment with 5 μg/ml of PZQ for 48 h; D. Negative control, treatment with
AR9 carrier only for 72 h.
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obtained 10 candidate compounds as well as their bind-
ing free energy with SjAR and HasAR were listed in
Table 2.
Inhibition studies on cultured worms
The effects of the identified compounds on adult worms
were observed by culturing the worms in medium
containing different amounts of each compound, and
death rates as well as morphological alterations wereFigure 4 SEM images of the tegument of adult worms. A and B
were worms treated with 10 μg/ml of AR9; C. Positive control group,
treated with 10 μg/ml of PZQ; D. Normal control, paired worms
treated with the AR9 carrier alone.monitored. In the primary screening, two compounds,
AR6 and AR9, exhibited good inhibition ability on cul-
tured worms. AR6 resulted in 75% mortality after 72 h,
but the effect was limited to 50 μg/ml. A similar effect
was observed for AR9 with activity at a lower concentra-
tion; thus, it was selected for the secondary screening to
confirm the efficacy of AR9 and further determine its
LC50 value. Here, 10 μg/ml of AR9 resulted in 91.67%
mortality over 72 h, and at 20 μg/ml, 100% mortality
over 48 h was observed. In contrast, worms treated with
equal volume of DMSO maintained a good activity
throughout the whole experimental period (Figure 2).Figure 5 The effect of compound AR9 on rSjAR enzymatic
activity. The concentrations of AR9 were 5 μg/ml (triangle), 10 μg/
ml (square) and 20 μg/ml (diamond). The AR9 blank was used as a
control (circle). The rSjAR concentration in each group was 0.15 μM.
The assay was performed independently three times. The
background was removed from the data shown here.
Figure 6 The cytotoxicity of compound AR9 against host cells.
The cell activity of compound-carrier alone treated group was
defined as 100%. The relative cell activity values of other
experimental groups were calculated by comparing with the control
group. The cytotoxicity was determined by Counting Kit-8 analysis,
as described in the Methods section.
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SPSS 18.0 was 5.72 μg/ml (16.42 μM), with a 95% confi-
dence interval of 4.37 μg/ml-7.91 μg/ml.
Optical images revealed that worms treated with com-
pound AR9 turned black, and obvious damage to the tegu-
ment was also observed (Figure 3A and 3B). As a positive
control, PZQ induced local drastic contracture, which was
consistent with previous studies [28] (Figure 3C). In con-
trast, these morphological alterations were not observed
in the compound-carrier treated group (Figure 3D).
SEM images further confirmed the results of micros-
copy. Severe wrinkles and extensive small blebs were ob-
served on the tegument layer of AR9-treated worms
(Figure 4A and 4B), while PZQ treatment resulted in
many ruptures of the tegument layer (Figure 4C). In
contrast, the surface of the schistosomes in the control
group was very smooth and exhibited a dense network
structure (Figure 4D).
Compound AR9 target validation
To verify that SjAR is indeed the target of compound AR9,
we assessed the effect of AR9 on rSjAR enzymatic activity.
A concentration-dependent inhibition of rSjAR activity was
observed. Compared with the compound-carrier-treated
group (0.4% DMSO), AR9 at concentrations of 10 μg/ml
and 20 μg/ml reduced rSjAR activity by 42.31% and
88.46%, respectively (Figure 5). The half-maximal inhibitory
concentration (IC50) calculated by SPSS 18.0 was 11.75
μg/ml (33.72 μM) in the first 10 min, with a 95% confi-
dence interval of 8.87 μg/ml −12.57 μg/ml.
Cytotoxicity assay
To assess the cytotoxicity of compound AR9, three differ-
ent cell lines (liver carcinoma cells, Hep G2; kidney cells,
293T and breast cells, Hela) from H. sapiens were selected
as experimental toxicity screens. For comparison, the ac-
tivity of all the cells was not significantly affected by ex-
posure to 20 μg/ml of AR9 for 72 h (especially in the Hep
G2 cells, where almost no cytotoxicity was observed),
while AR9 at 10 μg/ml led to over 90% worm mortality
over the same time period (Figure 2 and Figure 6).
Discussion
The antioxidant defense system plays a key role in the
physiological functions of an organism [32]. For schisto-
somes, there have been many studies showing that this
system protects the worms from host ROS attack; there-
fore, the associated enzymes are usually considered to be
potential drug-discovery targets [11,33]. S. japonicum al-
dose reductase, an important enzyme involved in this
system, was predicted as a potential drug target. In this
study, we firstly obtained the SjAR crystal structure
through the X-ray diffraction method, on which a virtual
screening and experimental validation strategy was appliedto screen antischistosomal lead compounds. Finally, one
compound, renamed as AR9, was determined to have ef-
fective antischistosomal activity but relatively low cytotox-
icity towards host cells, which suggested that it has the
potential as a lead compound from our selected candidate
inhibitors for further drug development.
Although no research has reported the SjAR before,
the HsaAR has long been considered to be a potential
target for therapies for diabetes and cancer [20,34], and
a large number of inhibitors have been identified over
the last 30 years. In this study, we also tested the inhibi-
tory activity of two known HsaAR inhibitors (epalrestat
and quercetin) on cultured worms, but neither of them
exhibited significant activity in vitro (data not shown).
This may be because of their specificity for targeting
HsaAR protein or their failure to reach the target area in
schistosomes. In contrast, the compound AR9 exhibited
not only a strong inhibition of rSjAR enzymatic activity
(IC50 =11.75 μg/ml) but also significant inhibitory activ-
ity of cultured worms (LC50 =5.72 μg/ml). In this study,
we also attempted to obtain the LC50 value of the
current drug PZQ for comparison of the corresponding
LC50 of AR9. It is of note that although the motor activ-
ity of worms exposed to different concentrations of PZQ
(1.25 μg/ml-40 μg/ml) decreased significantly in a short
time, however, the oral sucker and ventral sucker
remained active for a relatively long period, and these
worms couldn’t be judged as dead according to the death
definition described in the Methods section, so we could
not provide the accurate LC50 value of PZQ. We acknow-
ledge that the efficacy of AR9 on schistosomes is not as
good as PZQ, however, this study is still valuable. As
shown in Figure 7, 10 μg/ml of PZQ exhibited no inhib-
ition on rSjAR enzymatic activity which indicates that
compounds targeting SjAR may have a different mechan-
ism of action compared to PZQ. This result provides the
Figure 7 The effect of PZQ on rSjAR enzymatic activity. The
concentration of PZQ was 10 μg/ml (diamond), while PZQ blank
group was used as control (circle). The rSjAR concentration in each
group was 0.15 μM.
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Combination therapy is considered to be an effective ap-
proach to prevent the emergence of PZQ resistance. The
effectiveness of artemisinin derivatives in combination
with PZQ has been demonstrated [35]; however, because
artemisinin derivatives are effective anti-malaria drugs,
there is still concern about the induction of drug-resist
malaria. The results from this study avoid that concern
since these compounds have not been used as anti-
malarial drugs.
In this study, we also tested the enzyme inhibition for
all of the 10 small molecule compounds (CompoundFigure 8 The models of compound AR9 docked into the SjAR structu
AR9. The structure of SjAR is shown in a cartoon representation, with α-hel
Compound AR9, located in the interior of a hydrophobic pocket, is colored
shown with a stick model. View is from the bottom of the (α/β) 8 barrel. B.
indicates compound AR9. Polar and non-polar amino acids are colored ma
model indicates the ligand exposure area. The figure is generated with sofAR8 was not analyzed because of its low solubility) and
we tried to find whether there was a positive correlation
between enzyme inhibition and parasite growth inhib-
ition. The results showed that, besides AR9, compounds
AR1, AR3, AR5 and AR6 also exhibited a certain degree
of inhibition on rSjAR enzymatic activity (for AR1, AR3
and AR5, the IC50 values were less than 10 μg/ml, while
for AR6, the IC50 value was greater than 20 μg/ml).
However, none of these compounds showed significant
inhibitory activity on the cultured worms, except that
AR6 resulted in 75% mortality in 72 h at a concentration
of 50 μg/ml. Therefore, no significant correlation was
established between SjAR inhibition and adult worm
killing in vitro. The reason for this might be explained
by other factors, such as compound molecular weight,
solubility or their different pharmacokinetics in vivo,
which could also affect the lack of correlation of the en-
zyme inhibition assay with activity on cultured worms.
The identified compound, AR9, has two linked anth-
raquinone scaffolds, and its name is bianthrone or
dianthrone. Although anthraquinone scaffolds usually have
multiple molecular targets which usually result in their
promiscuity, there are indeed some cases that have suc-
cessfully made the anthraquinone compound into drugs by
introducing certain groups. Mitoxantrone, pixantrone and
the anthracyclines, all of which are anthraquinone deriva-
tives, have already been used as effective drugs for cancer
treatment [36-38]. Additionally, rufigallol, another anthra-
quinone derivative, also exhibits significant toxic to the
malaria parasite Plasmodium falciparum [39]. Therefore,
although the current structure of AR9 seems unsuitable
for a drug, improved derivatives could also be designedre. A. The predicted overall structure of SjAR bound with compound
ices colored red, β-sheets colored yellow and loops colored green.
blue. The nearby residues surrounding AR9 are colored magenta and
The interactions between compound AR9 and SjAR. The arrow
genta and green, respectively. Blue background on AR9 structural
tware Molecular Operating Environment 2011 (MOE).
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actually the major active ingredient of a widely used
Chinese herbal medicine named rheum palmatum, which
has been demonstrated to effectively inhibit bacteria, fungi
and viruses [40,41]. These studies further support the
speculation that AR9 has the potential to become a novel
antischistosomal lead compound.
Molecular docking analysis showed that AR9 located
to the interior of the pocket composed of the residues
Val47, Tyr48, Trp79, His110, Trp111, Phe122, Lys257 and
Phe293. AR9 can bind with the residues Tyr48 and Lys257
through the established hydrogen bonds (Figure 8). It is
noteworthy that although AR9 has a two-fold symmetry
in its scaffold, only one of the anthraquinone moieties
interacts with the SjAR protein, so the second moiety
seems redundant. However, when we removed the other
half of the AR9 structure and performed the docking
process again, the resulting prototype anthraquinone
structure showed poor binding ability with SjAR protein.
A significantly difference was that the previously existing
hydrogen bonds between AR9 and SjAR protein residues
(Tyr48 and Lys257) were not established as expected, and
meanwhile, no other residues newly-participated in the
combination with the prototype anthraquinone. The re-
sult might be explained that the second moiety changing
the distribution of the electron cloud of the binding re-
gions, thereby facilitating the binding of the first moiety.
However, the true binding model between a small mol-
ecule and its target protein can only be obtained by ana-
lyzing the SjAR-AR9 complex structure.
In this study, we have attempted to obtain the crystal
structure of SjAR complexed with compound AR9
through co-crystallization. However, this was very diffi-
cult to achieve because of the relatively lower solubility of
AR9. AR9 is soluble in DMSO, but less soluble in water.
When the concentration of AR9 in water was higher than
50 μg/ml, some precipitation would occur. Meanwhile, the
optimized SjAR protein crystallization concentration is
12 mg/ml (approximately 0.31 mM), so even assuming
that one SjAR protein molecule only binds to one com-
pound molecule, the minimum concentration of AR9
should be 119 μg/ml. However, large amounts of precipi-
tation have already occurred at that concentration. An al-
ternative strategy is to introduce a polar group in the AR9
structure (ensuring that this change does not significantly
affect its antischistosomal activity) to increase its solubil-
ity, and then attempt co-crystallization.
The majority of previous studies have focused either on
the screening and designing of inhibitors of a known drug
target or on the analysis of antischistosomal activity of po-
tential drugs [12,42,43], while the work presented here
bridges the gap between virtual screening and experimen-
tal validation, providing an effective and economical strat-
egy to discover antischistosomal lead compounds. Morework, such as in vivo experiments, the design of deriva-
tives and optimization of complex crystallization condi-
tions are still needed in further studies.
Conclusions
The work presented here developed an effective and eco-
nomical strategy, which integrates virtual screening and ex-
perimental validation for the development of new anti-
parasitic drugs. In this study, we firstly resolved the SjAR
structure and identified one compound, bianthrone, which
may become a new potential lead compound for developing
novel antischistosomal drugs based on this structural model.
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